Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Prelude Therapeutics Inc (PRLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: PRLD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.77% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.35M USD | Price to earnings Ratio - | 1Y Target Price 3.33 |
Price to earnings Ratio - | 1Y Target Price 3.33 | ||
Volume (30-day avg) 173006 | Beta 1.42 | 52 Weeks Range 0.63 - 6.80 | Updated Date 03/27/2025 |
52 Weeks Range 0.63 - 6.80 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -845.78% |
Management Effectiveness
Return on Assets (TTM) -38.54% | Return on Equity (TTM) -69.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -80317613 | Price to Sales(TTM) 5.48 |
Enterprise Value -80317613 | Price to Sales(TTM) 5.48 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.54 | Shares Outstanding 42304400 | Shares Floating 17639003 |
Shares Outstanding 42304400 | Shares Floating 17639003 | ||
Percent Insiders 9.71 | Percent Institutions 89.73 |
Analyst Ratings
Rating 3.2 | Target Price 5 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell 1 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Prelude Therapeutics Inc
Company Overview
History and Background
Prelude Therapeutics Inc. was founded in 2016 and is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies precisely targeted to cancer. They are headquartered in Wilmington, Delaware.
Core Business Areas
- Discovery and Development of Small Molecule Therapies: Focuses on developing therapies targeted to specific unmet needs in cancer treatment.
Leadership and Structure
The company's leadership team includes individuals with expertise in drug development, oncology, and business operations. The organizational structure includes research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- PRT-SITA: A selective CDK4/6 inhibitor in Phase 2 clinical trials for hormone receptor-positive (HR+) advanced breast cancer. Competitors include Eli Lilly (Verzenio), Pfizer (Ibrance), and Novartis (Kisqali).
- PRT3645: A highly selective, potent and orally bioavailable SMARCA2 degrader in Phase 1 clinical trials for various cancers. Competitors include other companies developing SMARCA2 inhibitors, though this target is relatively novel.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, characterized by significant regulatory hurdles and the need for substantial investment in research and development. The oncology market is a major segment with increasing demand for targeted therapies.
Positioning
Prelude Therapeutics is a clinical-stage company focused on precision oncology. Their competitive advantage lies in their expertise in small molecule drug discovery and development, and their pipeline of targeted therapies.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Prelude Therapeutics targets specific segments within this market, such as HR+ breast cancer and SMARCA2-driven cancers. Their positioning relative to the TAM is dependent on the success of their clinical trials and eventual commercialization.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in drug discovery
- Targeted approach to oncology
- Pipeline of clinical-stage assets
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal discovery and external collaborations
- Growing demand for targeted cancer therapies
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other oncology drug developers
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- LLY
- PFE
- NVS
Competitive Landscape
Prelude Therapeutics faces competition from established pharmaceutical companies and other biotechnology firms. Their success depends on demonstrating superior efficacy and safety compared to existing therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by advancement of pipeline assets through clinical trials. No revenue at this stage, but growing R&D investment indicates growth.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and eventual commercialization of its drug candidates. Analyst estimates depend on achieving these milestones.
Recent Initiatives: Recent initiatives include initiating and progressing clinical trials for their lead drug candidates, and expanding their pipeline through internal discovery and strategic collaborations.
Summary
Prelude Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing targeted cancer therapies. Their pipeline of clinical-stage assets and experienced management team are key strengths. However, they face risks associated with clinical trial outcomes, regulatory hurdles, and competition. The company's future success hinges on positive clinical trial results and successful commercialization of their drug candidates.
Similar Companies
- ARRY
- CRVS
- MRTX
- GILD
Sources and Disclaimers
Data Sources:
- Prelude Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on available information and may not be entirely accurate. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prelude Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2020-09-25 | Founder, CEO & Director Dr. Krishna Vaddi D.V.M., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://preludetx.com |
Full time employees 131 | Website https://preludetx.com | ||
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.